Long-Term Safety of Lutetium (177Lu) Vipivotide Tetraxetan in Participants With Prostate Cancer
Conditions
Prostate Cancer
Simple summaryAI-assisted
This summary is produced by a language model and is experimental. It may be incomplete or inaccurate and is not a substitute for professional medical advice.
Locations
Mayo Clinic Arizona, Scottsdale, Arizona, United States
Contact: Principal Investigator (Cassandra Moore)St. Joseph Hospital, Orange, California, United States
Contact: Principal Investigator (Timothy Byun)Providence Saint Johns Health Ctr, Santa Monica, California, United States
Contact: Principal Investigator (Przemyslaw Twardowski)University of Colorado, Aurora, Colorado, United States
Contact: Principal Investigator (Muthiah Nachiappan)Hartford Hospital, Hartford, Connecticut, United States
Contact: Principal Investigator (Andrew Salner)VA Medical Center, Washington D.C., District of Columbia, United States
Contact: Principal Investigator (Frank Liu)Mayo Clinic Jacksonville, Jacksonville, Florida, United States
Contact: Principal Investigator (Winston Tan)University Cancer and Blood Center LLC, Athens, Georgia, United States
Contact: Principal Investigator (Petros Nikolinakos)Parkview Research Center, Fort Wayne, Indiana, United States
Contact: Principal Investigator (Brian Chang)Tulane Cancer Center, New Orleans, Louisiana, United States
Contact: Principal Investigator (Brian Lewis)Ochsner Clinic Foundation, New Orleans, Louisiana, United States
Contact: Principal Investigator (Stephen Bardot)Corewell Health William Beaum Hosp, Royal Oak, Michigan, United States
Contact: Principal Investigator (Andrew Thompson)Mayo Clinic Rochester, Rochester, Minnesota, United States
Contact: Principal Investigator (Brian Costello)University of Mississippi Med Ctr, Jackson, Mississippi, United States
Contact: Principal Investigator (John Clark Henegan)Wash U School of Medicine, St Louis, Missouri, United States
Contact: Principal Investigator (Hyun Kim)Urology Cancer Center PC, Omaha, Nebraska, United States
Contact: Principal Investigator (Luke Nordquist)Nebraska Cancer Specialists, Omaha, Nebraska, United States
Contact: Principal Investigator (Ralph Hauke)Montefiore Medical Center, The Bronx, New York, United States
Contact: Principal Investigator (Benjamin A Gartrell)Duke University Medical Center, Durham, North Carolina, United States
Contact: Principal Investigator (Daniel J George)Cleveland Clinic Foundation, Cleveland, Ohio, United States
Contact: Principal Investigator (Shilpa Gupta)Univ of Pittsburgh Medical Center, Pittsburgh, Pennsylvania, United States
Contact: Principal Investigator (Leonard Appleman)Univ of Texas Southwest Med Center, Dallas, Texas, United States
Contact: Principal Investigator (Kevin Courtney)UT Health Science Center, Houston, Texas, United States
Contact: Principal Investigator (Bo Chen)Onco Hemato Asso of SW Virginia, Roanoke, Virginia, United States
Contact: Principal Investigator (David Buck)Novartis Investigative Site, Linz, Austria
Novartis Investigative Site, Vienna, Austria
Novartis Investigative Site, Ghent, Belgium
Novartis Investigative Site, Montreal, Quebec, Canada
Novartis Investigative Site, Olomouc, Czechia
Novartis Investigative Site, Prague, Czechia
Novartis Investigative Site, Lyon, France
Novartis Investigative Site, Essen, Germany
Novartis Investigative Site, München, Germany
Novartis Investigative Site, Rostock, Germany
Novartis Investigative Site, Nijmegen, Gelderland, Netherlands
Novartis Investigative Site, Maastricht, Limburg, Netherlands
Novartis Investigative Site, Delft, South Holland, Netherlands
Novartis Investigative Site, L'Hospitalet de Llobregat, Barcelona, Spain
Novartis Investigative Site, Sabadell, Barcelona, Spain
Novartis Investigative Site, Majadahonda, Madrid, Spain
Novartis Investigative Site, Barcelona, Spain
Novartis Investigative Site, Barcelona, Spain
Novartis Investigative Site, Madrid, Spain
Novartis Investigative Site, Madrid, Spain
Novartis Investigative Site, Madrid, Spain
Novartis Investigative Site, Madrid, Spain
Novartis Investigative Site, Valencia, Spain
Novartis Investigative Site, Gothenburg, Sweden
Novartis Investigative Site, Stockholm, Sweden
Novartis Investigative Site, Sutton, Surrey, United Kingdom
Novartis Investigative Site, Barnet, United Kingdom
Novartis Investigative Site, Cambridge, United Kingdom
Novartis Investigative Site, Glasgow, United Kingdom
Novartis Investigative Site, Middlesbrough, United Kingdom
Study leads
Novartis Pharmaceuticals
Study Director
Novartis Pharmaceuticals